MedTrace Logo

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

NCT00811733 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2017-05-30

Study results available
· View outcomes & findings →

Summary

Given the tolerability and efficacy of ofatumumab in follicular lymphoma and Chronic Lymphocytic Leukemia, and the need to improve therapy for patients with WM utilizing a non-myelosuppressive agent this phase II trial of ofatumumab is being initiated in patients with Waldenstrom's Macroglobulinemia (WM).

Conditions

  • Waldenstrom Macroglobulinaemia

Interventions

BIOLOGICAL

Ofatumumab

Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-01
Primary Completion
2011-06-01
Completion
2014-02-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00811733 on ClinicalTrials.gov